Cargando…

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure

OBJECTIVE: Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. METHODS: Individual level...

Descripción completa

Detalles Bibliográficos
Autores principales: Norhammar, Anna, Bodegard, Johan, Vanderheyden, Marc, Tangri, Navdeep, Karasik, Avraham, Maggioni, Aldo Pietro, Sveen, Kari Anne, Taveira-Gomes, Tiago, Botana, Manuel, Hunziker, Lukas, Thuresson, Marcus, Banerjee, Amitava, Sundström, Johan, Bollmann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086499/
https://www.ncbi.nlm.nih.gov/pubmed/36781285
http://dx.doi.org/10.1136/heartjnl-2022-321702
_version_ 1785022166967779328
author Norhammar, Anna
Bodegard, Johan
Vanderheyden, Marc
Tangri, Navdeep
Karasik, Avraham
Maggioni, Aldo Pietro
Sveen, Kari Anne
Taveira-Gomes, Tiago
Botana, Manuel
Hunziker, Lukas
Thuresson, Marcus
Banerjee, Amitava
Sundström, Johan
Bollmann, Andreas
author_facet Norhammar, Anna
Bodegard, Johan
Vanderheyden, Marc
Tangri, Navdeep
Karasik, Avraham
Maggioni, Aldo Pietro
Sveen, Kari Anne
Taveira-Gomes, Tiago
Botana, Manuel
Hunziker, Lukas
Thuresson, Marcus
Banerjee, Amitava
Sundström, Johan
Bollmann, Andreas
author_sort Norhammar, Anna
collection PubMed
description OBJECTIVE: Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. METHODS: Individual level data from a contemporary cohort of 6 29 624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5 years. RESULTS: The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95% CI 74.0 to 76.4), 48.8% (40.9–56.8%) had ischaemic heart disease and 34.5% (29.4–39.6%) had diabetes. In 51 442 patients with a recorded ejection fraction (EF), 39.1% (30.3–47.8%) had a reduced, 18.8% (13.5–24.0%) had a mildly reduced and 42.1% (31.5–52.8%) had a preserved left ventricular EF. In 1 69 518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III–V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases. CONCLUSIONS: We estimate that 1–2% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management.
format Online
Article
Text
id pubmed-10086499
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100864992023-04-12 Prevalence, outcomes and costs of a contemporary, multinational population with heart failure Norhammar, Anna Bodegard, Johan Vanderheyden, Marc Tangri, Navdeep Karasik, Avraham Maggioni, Aldo Pietro Sveen, Kari Anne Taveira-Gomes, Tiago Botana, Manuel Hunziker, Lukas Thuresson, Marcus Banerjee, Amitava Sundström, Johan Bollmann, Andreas Heart Heart Failure and Cardiomyopathies OBJECTIVE: Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. METHODS: Individual level data from a contemporary cohort of 6 29 624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5 years. RESULTS: The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95% CI 74.0 to 76.4), 48.8% (40.9–56.8%) had ischaemic heart disease and 34.5% (29.4–39.6%) had diabetes. In 51 442 patients with a recorded ejection fraction (EF), 39.1% (30.3–47.8%) had a reduced, 18.8% (13.5–24.0%) had a mildly reduced and 42.1% (31.5–52.8%) had a preserved left ventricular EF. In 1 69 518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III–V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases. CONCLUSIONS: We estimate that 1–2% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management. BMJ Publishing Group 2023-04 2023-02-13 /pmc/articles/PMC10086499/ /pubmed/36781285 http://dx.doi.org/10.1136/heartjnl-2022-321702 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Heart Failure and Cardiomyopathies
Norhammar, Anna
Bodegard, Johan
Vanderheyden, Marc
Tangri, Navdeep
Karasik, Avraham
Maggioni, Aldo Pietro
Sveen, Kari Anne
Taveira-Gomes, Tiago
Botana, Manuel
Hunziker, Lukas
Thuresson, Marcus
Banerjee, Amitava
Sundström, Johan
Bollmann, Andreas
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title_full Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title_fullStr Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title_full_unstemmed Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title_short Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
title_sort prevalence, outcomes and costs of a contemporary, multinational population with heart failure
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086499/
https://www.ncbi.nlm.nih.gov/pubmed/36781285
http://dx.doi.org/10.1136/heartjnl-2022-321702
work_keys_str_mv AT norhammaranna prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT bodegardjohan prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT vanderheydenmarc prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT tangrinavdeep prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT karasikavraham prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT maggionialdopietro prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT sveenkarianne prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT taveiragomestiago prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT botanamanuel prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT hunzikerlukas prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT thuressonmarcus prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT banerjeeamitava prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT sundstromjohan prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure
AT bollmannandreas prevalenceoutcomesandcostsofacontemporarymultinationalpopulationwithheartfailure